Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF

AIMS: Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under‐prescription of beta‐blockers. Consequently, additional effective therapies are...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Heart Fail
Autori principali: Dewan, Pooja, Docherty, Kieran F., Bengtsson, Olof, de Boer, Rudolf A., Desai, Akshay S., Drozdz, Jaroslaw, Hawkins, Nathaniel M., Inzucchi, Silvio E., Kitakaze, Masafumi, Køber, Lars, Kosiborod, Mikail N., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe A., Merkely, Béla, Petrie, Mark C., Ponikowski, Piotr, Sabatine, Marc S., Schou, Morten, Sjöstrand, Mikaela, Solomon, Scott D., Verma, Subodh, Jhund, Pardeep S., McMurray, John J.V.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Ltd. 2021
Soggetti:
Clinical Trials: Dapa‐hf
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247863/
https://ncbi.nlm.nih.gov/pubmed/33368858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.2083
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi